Last reviewed · How we verify
Scripps Poway Eyecare and Optometry — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Systane Complete Multi-Dose PF | Systane Complete Multi-Dose PF | marketed | ||||
| Refresh Optive MEGA-3 | Refresh Optive MEGA-3 | marketed | Artificial tear lubricant / Ocular surface protectant | Ophthalmology | ||
| Walgreen's Lubricant Balance | Walgreen's Lubricant Balance | marketed | Artificial tear / Lubricant | Ophthalmology | ||
| Systane PRO | Systane PRO | marketed | Ophthalmic lubricant / artificial tear | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 1 shared drug class
- EMS · 1 shared drug class
- Massachusetts Eye and Ear Infirmary · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Scripps Poway Eyecare and Optometry:
- Scripps Poway Eyecare and Optometry pipeline updates — RSS
- Scripps Poway Eyecare and Optometry pipeline updates — Atom
- Scripps Poway Eyecare and Optometry pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Scripps Poway Eyecare and Optometry — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scripps-poway-eyecare-and-optometry. Accessed 2026-05-16.